111 related articles for article (PubMed ID: 21864886)
1. A prospective, randomized trial of integrative medicine for women with ovarian cancer.
Judson PL; Dickson EL; Argenta PA; Xiong Y; Geller MA; Carson LF; Ghebre R; Jonson AL; Downs LS
Gynecol Oncol; 2011 Nov; 123(2):346-50. PubMed ID: 21864886
[TBL] [Abstract][Full Text] [Related]
2. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
Brotto L; Brundage M; Hoskins P; Vergote I; Cervantes A; Casado HA; Poveda A; Eisenhauer E; Tu D; ; ;
Support Care Cancer; 2016 Mar; 24(3):1241-9. PubMed ID: 26304156
[TBL] [Abstract][Full Text] [Related]
3. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
[TBL] [Abstract][Full Text] [Related]
4. Quality-of-life outcomes in patients with gynecologic cancer referred to integrative oncology treatment during chemotherapy.
Ben-Arye E; Samuels N; Schiff E; Raz OG; Sharabi IS; Lavie O
Support Care Cancer; 2015 Dec; 23(12):3411-9. PubMed ID: 25752885
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in ovarian cancer patients receiving chemotherapy.
Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
[TBL] [Abstract][Full Text] [Related]
6. Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy treatment.
Le T; Leis A; Pahwa P; Wright K; Ali K; Reeder B; Kinderchuck M; Ward K
J Obstet Gynaecol Can; 2004 Jul; 26(7):627-31. PubMed ID: 15248931
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
8. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016).
Harano K; Terauchi F; Katsumata N; Takahashi F; Yasuda M; Takakura S; Takano M; Yamamoto Y; Sugiyama T
Ann Oncol; 2014 Jan; 25(1):251-7. PubMed ID: 24356636
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
[TBL] [Abstract][Full Text] [Related]
10. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
Ramondetta LM; Hu W; Thaker PH; Urbauer DL; Chisholm GB; Westin SN; Sun Y; Ramirez PT; Fleming N; Sahai SK; Nick AM; Arevalo JMG; Dizon T; Coleman RL; Cole SW; Sood AK
Gynecol Oncol; 2019 Sep; 154(3):524-530. PubMed ID: 31353053
[TBL] [Abstract][Full Text] [Related]
11. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.
Hess LM; Huang HQ; Hanlon AL; Robinson WR; Johnson R; Chambers SK; Mannel RS; Puls L; Davidson SA; Method M; Lele S; Havrilesky L; Nelson T; Alberts DS
Gynecol Oncol; 2015 Dec; 139(3):541-5. PubMed ID: 26456812
[TBL] [Abstract][Full Text] [Related]
12. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC; Scambia G; Bologna A; Signoriello S; Vergote I; Baumann K; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Gallo C; Pignata S; Perrone F
Ann Oncol; 2018 May; 29(5):1189-1194. PubMed ID: 29462248
[TBL] [Abstract][Full Text] [Related]
13. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
14. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
Stark D; Nankivell M; Pujade-Lauraine E; Kristensen G; Elit L; Stockler M; Hilpert F; Cervantes A; Brown J; Lanceley A; Velikova G; Sabate E; Pfisterer J; Carey MS; Beale P; Qian W; Swart AM; Oza A; Perren T
Lancet Oncol; 2013 Mar; 14(3):236-43. PubMed ID: 23333117
[TBL] [Abstract][Full Text] [Related]
15. Exploring integrative medicine for back and neck pain - a pragmatic randomised clinical pilot trial.
Sundberg T; Petzold M; Wändell P; Rydén A; Falkenberg T
BMC Complement Altern Med; 2009 Sep; 9():33. PubMed ID: 19735542
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer.
Hess LM; Chambers SK; Hatch K; Hallum A; Janicek MF; Buscema J; Borst M; Johnson C; Slayton L; Chongpison Y; Alberts DS
J Support Oncol; 2010; 8(6):252-8. PubMed ID: 21265392
[TBL] [Abstract][Full Text] [Related]
17. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists.
Calhoun EA; Bennett CL; Peeples PA; Lurain JR; Roland PY; Weinstein JM; Fishman DA
Gynecol Oncol; 1998 Dec; 71(3):369-75. PubMed ID: 9887233
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
[TBL] [Abstract][Full Text] [Related]
19. Integrating a complementary medicine consultation for women undergoing chemotherapy.
Ben-Arye E; Schiff E; Raz OG; Samuels N; Lavie O
Int J Gynaecol Obstet; 2014 Jan; 124(1):51-4. PubMed ID: 24140221
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
